Median overall survival (OS) in investigated prognostic subgroups
| Variable . | No. of patients (%) . | Median OS (95% CI), y . |
|---|---|---|
| CLLU1 expression | 175 (100) | |
| CLLU1 less than 40-fold | 101 (58) | 8.1 (6.7-11.1) |
| CLLU1 at least 40-fold | 74 (42) | 5.0 (2.9-7.1) |
| Clinical stage, Binet | 175 (100) | |
| Stage A | 115 (66) | 8.1 (7.1-10.3) |
| Stage B or C | 60 (34) | 3.8 (2.2-6.5) |
| Mutational status | 136 (77) | |
| IgVH homology less than 98% | 88 (65) | 10.3 (8.4-∞) |
| IgVH homology at least 98% | 48 (35) | 3.6 (2.3-6.2) |
| ZAP-70 expression | 132 (75) | |
| ZAP-70 less than 20% | 51 (39) | Not reached (7.0-∞) |
| ZAP-70 at least 20% | 81 (61) | 4.6 (3.8-7.10) |
| CD38 expression | 130 (74) | |
| CD38 less than 20% | 91 (70) | 9.3 (6.7-∞) |
| CD38 at least 20% | 39 (30) | 4.0 (2.9-7.1) |
| Cytogenetics | 126 (72) | |
| del(13q)/normal/trisomy 12 | 92 (73) | 9.4 (7.1-∞) |
| del(11q)/del(17p) | 34 (27) | 2.3 (1.2-6.2) |
| Variable . | No. of patients (%) . | Median OS (95% CI), y . |
|---|---|---|
| CLLU1 expression | 175 (100) | |
| CLLU1 less than 40-fold | 101 (58) | 8.1 (6.7-11.1) |
| CLLU1 at least 40-fold | 74 (42) | 5.0 (2.9-7.1) |
| Clinical stage, Binet | 175 (100) | |
| Stage A | 115 (66) | 8.1 (7.1-10.3) |
| Stage B or C | 60 (34) | 3.8 (2.2-6.5) |
| Mutational status | 136 (77) | |
| IgVH homology less than 98% | 88 (65) | 10.3 (8.4-∞) |
| IgVH homology at least 98% | 48 (35) | 3.6 (2.3-6.2) |
| ZAP-70 expression | 132 (75) | |
| ZAP-70 less than 20% | 51 (39) | Not reached (7.0-∞) |
| ZAP-70 at least 20% | 81 (61) | 4.6 (3.8-7.10) |
| CD38 expression | 130 (74) | |
| CD38 less than 20% | 91 (70) | 9.3 (6.7-∞) |
| CD38 at least 20% | 39 (30) | 4.0 (2.9-7.1) |
| Cytogenetics | 126 (72) | |
| del(13q)/normal/trisomy 12 | 92 (73) | 9.4 (7.1-∞) |
| del(11q)/del(17p) | 34 (27) | 2.3 (1.2-6.2) |
P values were all less than .001.